Substance Use Tools & Resources    

This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.

This program — Support for Hospital Opioid Use Treatment (Project SHOUT) — provides clinical leaders with the tools they need to start and maintain patients on buprenorphine or methadone during hospitalizations for any condition, be it medical, surgical, or obstetric.

Guides States, Tribes, and local communities on best practices for collaborative treatment approaches for women with SUDs. Highlights data on the effects of opioids on pregnant women and the risks and benefits associated with MAT.

Provides information for pregnant women about how taking methadone or buprenorphine may affect delivery, breastfeeding, and newborn infants.

These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder.

Gives clinicians information about treating pregnant women with buprenorphine.

The PRO screens pregnant women for psychosocial risk factors that may affect a healthy pregnancy or birth or impede a woman’s ability to comply with prenatal care recommendations.

A Practice Guideline which includes treatment recommendations for patients with substance use disorders, as well as background information and a review of available evidence.

This screening device is often used as a way to begin discussion about drug and alcohol use. Any woman who answers yes to one or more questions should be referred for further assessment.

The LactMed® database contains information on drugs and other chemicals to which breastfeeding mothers may be exposed. It includes information on the levels of such substances in breast milk and infant blood, and the possible adverse effects in the nursing infant.